Dendreon Corp fka DNDNQ

[bio_guyo]

Comparing Provenge and GVAX at this stage is like judging apples and oranges. The clinical data to date are from trials with entirely different designs. The 9901 and 9902b trials were crossover in design, so that the longest any patient in the control arm was deprived of Provenge was 6 months. GVAX, on the other hand, had 4 patients excluded from the phase II study for reasons that were not articulated in today's press release. Its phase III trial design lacks crossover, so that a group maintained on GVAX plus taxotere will be compared with the control arm receiving taxotere alone and never receiving GVAX.